L
Lanna Feldman
Researcher at Boston Children's Hospital
Publications - 18
Citations - 1126
Lanna Feldman is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 13 publications receiving 933 citations. Previous affiliations of Lanna Feldman include Tufts Center for the Study of Drug Development.
Papers
More filters
Journal ArticleDOI
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
TL;DR: The study examined the development histories of these investigational compounds from the time point at which they first entered clinical testing through June 2009 and estimated clinical approval success rates and phase transition probabilities differed significantly by therapeutic class.
Journal ArticleDOI
Clinical Approval Success Rates for Investigational Cancer Drugs
TL;DR: The authors examined development risks for new cancer drugs and found success rates of second and third indications were found to be highly dependent on the success or failure of the first indication pursued.
Journal ArticleDOI
Trends in Pediatric ACL Reconstruction From the PHIS Database.
TL;DR: The number of ACL reconstructions performed for children and adolescents in pediatric hospitals nationwide markedly increased by nearly 3 times relative to orthopaedic surgeries over a recent 10-year period.
Journal ArticleDOI
Pediatric orthopaedic lower extremity trauma and venous thromboembolism
Robert F. Murphy,Robert F. Murphy,Manahil Naqvi,Patricia E. Miller,Lanna Feldman,Benjamin J. Shore +5 more
TL;DR: The incidence of VTE events associated with lower extremity orthopaedic trauma is 0.058 %.
Journal ArticleDOI
Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
M Orfali,Lanna Feldman,V Bhattacharjee,P Harkins,S Kadam,C Lo,M Ravi,D T Shringarpure,Jack Mardekian,C Cassino,T Cote +10 more
TL;DR: It is concluded that small studies of appropriate design can support US FDA approval of new medicines for rare diseases, and proportions with randomization, blinding, and placebo‐controlled clinical end points were similar.